Allergan Plc isn’t looking at any large deals, Chief Executive Officer Brent Sanders said, after the drugmaker posted second-quarter sales that fell short of analysts’ estimates.
Revenue at Allergan, which ended its $160 billion planned merger with Pfizer Inc. in April, rose 1.5 percent to $3.68 billion last quarter. That was shy of the $3.72 billion average of estimates compiled by Bloomberg.
Revenue at Allergan, which ended its $160 billion planned merger with Pfizer Inc. in April, rose 1.5 percent to $3.68 billion last quarter. That was shy of the $3.72 billion average of estimates compiled by Bloomberg.
